Long-term outcome of ATG vs. Basiliximab induction

European Journal of Clinical Investigation

Volumn 41, Issue 9, 2011, Pages 971-978

  Ulrich, Frank ^a   Niedzwiecki, Sebastian ^a,b   Pascher, Andreas ^a   Kohler, Sven ^a   Weiss, Sascha ^a   Fikatas, Panagiotis ^a   Schumacher, Guido ^a   May, Gottfried ^a   Reinke, Petra ^a   Neuhaus, Peter ^a   Tullius, Stefan G ^c   Pratschke, Johann ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ATG; Basiliximab; Induction therapy; Renal transplantation

Indexed keywords

BASILIXIMAB; METHYLPREDNISOLONE; OKT 3; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BLOOD TOXICITY; COLD ISCHEMIA; COMPARATIVE EFFECTIVENESS; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DIALYSIS; DRUG FEVER; DRUG INDUCED CANCER; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LEUKOPENIA; LYMPHOCELE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUROLOGIC DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SURVIVAL; THROMBOCYTOPENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960974037     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02490.x     Document Type: Article

References (36)

1. Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48-56.
2. Szczech LA, Berlin JA, Aradhye S, Grossman RA, Feldman HI. Effect of antilymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997;8:1771-7.
3. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998;128:817-26.
4. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy 2006;26:1771-83.
5. Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995;60:748-56.
6. Kovarik J, Wolf P, Cisterne JM, Mourad G, Lebranchu Y, Lang P et al. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation 1997;64:1701-5.
7. Kovarik JM, Rawlings E, Sweny P, Fernando O, Moore R, Griffin PJ et al. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients. Transpl Int 1996;9(Suppl. 1):S32.
8. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51:669-73.
9. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011-8.
10. Muller T, Ruffingshofer D, Bidmon B, Arbeiter K, Balzar E, Aufricht C. Reduction of delayed renal allograft function using sequential immunosuppression. Pediatr Nephrol 2001;16:613-7.
11. Cantarovich D, Karam G, Giral-Classe M, Hourmant M, Dantal J, Blancho G et al. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998;54:1351-6.
12. Smith JM, McDonald RA. Renal transplantation in adolescents. Adolesc Med Clin 2005;16:201-4.
13. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002;13:769-72.
14. Mourad G, Rostaing L, Legendre C, Garrigue V, Thervet E, Durand D. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004;78:584-90.
15. Tullius SG, Pratschke J, Strobelt V, Kahl A, Reinke P, May G et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant Proc 2003;35:2100-1.
16. Kyllonen LE, Eklund BH, Pesonen EJ, Salmela KT. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 2007;84:75-82.
17. Haririan A, Morawski K, Sillix DH, El-Amm JM, Garnick J, West MS et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005;79:716-21.
18. Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001;72:1915-9.
19. Halloran PF, Aprile MA, Farewell V, Ludwin D, Smith EK, Tsai SY et al. Early function as the principal correlate of graft survival. A multivariate analysis of 200 cadaveric renal transplants treated with a protocol incorporating antilymphocyte globulin and cyclosporine. Transplantation 1988;46:223-8.
20. Kaden J, Strobelt V, May G. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation. Transplant Proc 1998;30:4011-4.
21. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-77.
22. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997;350:1193-8.
23. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric antiinterleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation 1999;67:276-284.
24. Ponticelli C, Yussim A, Cambi V, Legendre C, Rizzo G, Salvadori M et al. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001;72:1261-7.
25. Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric antiinterleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetilcontaining triple therapy in renal transplantation. Transplantation 2003;75:37-43.
26. Pascual J, Segoloni G, Gonzalez Molina M, del Castillo D, Capdevila L, Arias M et al. Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: results of a European trial with 3-year follow up. Transplant Proc 2003;35:1701-3.
27. Segoloni G, Bonomini V, Maresca MC, Arisi L, Gonzalez-Molina M, Tarantino A et al. Tacrolimus is highly effective in both dual and triple therapy regimens following renal transplantation. Spanish and Italian Tacrolimus Study Group. Transpl Int 2000;13(Suppl. 1):S336-40.
28. Charpentier B. A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients. Transplant Proc 2002;34:1625-6.
29. Kaden J, May G, Strobelt V, Groth J, Muller P. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Transplant Proc 1997;29:344-7.
30. Turunen AJ, Lindgren L, Salmela KT, Kyllonen LE, Makisalo H, Siitonen SM et al. Association of graft neutrophil sequestration with delayed graft function in clinical renal transplantation. Transplantation 2004;77:1821-6.
31. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992;53:68-72.
32. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995;123:18-26.
33. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003;63:2803-35.
34. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:2134-43.
35. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008;8:69-77.
36. Yang S, Wang D, Wu W, Lin W, Xu T, Cai J et al. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Transpl Immunol 2008;18:281-5.